J Korean Diabetes.
2013 Sep;14(3):111-119. 10.4093/jkd.2013.14.3.111.
Comparison of DPP-4 Inhibitors
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr
- KMID: 2173918
- DOI: http://doi.org/10.4093/jkd.2013.14.3.111
Abstract
- During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them.
MeSH Terms
-
Adamantane
Diabetes Mellitus
Dipeptides
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemia
Hypoglycemic Agents
Incretins
Insulin
Nitriles
Piperidines
Purines
Pyrazines
Pyrrolidines
Quinazolines
Triazoles
Uracil
Linagliptin
Sitagliptin Phosphate
Adamantane
Dipeptides
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Incretins
Insulin
Nitriles
Piperidines
Purines
Pyrazines
Pyrrolidines
Quinazolines
Triazoles
Uracil
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
- DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes
- New Therapeutics for Diabetes Using Incretin Hormone
- Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
- Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008–2016
